{"id":"hb1801","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HB1801 functions as a bispecific monoclonal antibody designed to target multiple immune regulatory pathways. By binding to two different checkpoint molecules, it aims to overcome tumor immune evasion mechanisms and promote robust T-cell activation and proliferation against cancer cells.","oneSentence":"HB1801 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:50.907Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07441460","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2026-03-07","conditions":"Resectable HER2-positive Breast Cancer","enrollment":1800},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT07116824","phase":"PHASE2","title":"HB1801 Combined Treatment of HER2-positive Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":80},{"nctId":"NCT07083505","phase":"PHASE2","title":"A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-08-15","conditions":"Advanced Breast Cancer","enrollment":60},{"nctId":"NCT05838066","phase":"PHASE3","title":"Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2023-07-23","conditions":"First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer","enrollment":880},{"nctId":"NCT06747338","phase":"PHASE3","title":"A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-12-16","conditions":"Early or Locally Advanced HER2-positive Breast Cancer","enrollment":520},{"nctId":"NCT06296706","phase":"PHASE3","title":"A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-02-27","conditions":"Gastric Cancer","enrollment":630},{"nctId":"NCT06682611","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Runshi Pharmaceutical Technology Co., Ltd","startDate":"2024-11-13","conditions":"Unresectable Locally Advanced or Metastatic Solid Tumors","enrollment":380},{"nctId":"NCT06525350","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-07","conditions":"Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression","enrollment":256},{"nctId":"NCT06319313","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-05-01","conditions":"Squamous Cell Non-small Cell Lung Cancer","enrollment":534},{"nctId":"NCT06136988","phase":"PHASE1, PHASE2","title":"A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-12","conditions":"Locally Advanced Unresectable Esophageal Squamous Carcinoma","enrollment":129},{"nctId":"NCT05863325","phase":"PHASE2","title":"A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-06-27","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HB1801","genericName":"HB1801","companyName":"Shanghai JMT-Bio Inc.","companyId":"shanghai-jmt-bio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HB1801 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T-cell responses. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}